Table 1.
Demographic Data Before Hematopoietic Cell Transplantation
| No. | 66 |
| Age, mean (SD) | 52.2 (12.5) |
| Male, No. (%) | 37 (56.7) |
| Race/ethnicity, No. (%) | |
| Asian | 8 (11.9) |
| White | 51 (76.1) |
| Hispanic | 8 (11.9) |
| HCT-CI scorea | |
| <3 Comorbidities | 50 |
| ≥3 Comorbidities | 11 |
| Underlying reason for HCT, No. (%) | |
| AML | 20 (30.3) |
| ALL | 14 (21.2) |
| MDS | 12 (18.2) |
| CML | 6 (9.1) |
| CLL | 3 (4.5) |
| NHL | 6 (9.1) |
| HL | 2 (3.0) |
| Other | 3 (4.5) |
| Type of donor, No. (%) | |
| Match-related | 30 (45.5) |
| Unrelated-identical | 24 (36.4) |
| Unrelated-mismatched | 10 (15.2) |
| Haploidentical/cord | 2 (3) |
| Regimen, No. (%) | |
| Myeloablative | 37 (56.1) |
| Non-myeloablative | 19 (28.8) |
| Reduced intensity | 10 (15.2) |
| PFT characteristics before HCT, mean (SD) | |
| FEV1, L | 3.20 (0.76) |
| FEV1, % predicted | 100.5 (16.0) |
| FVC, L | 4.13 (0.98) |
| FVC, % predicted | 99.6 (13.8) |
| FEV1/FVC, % | 78.14 (7.64) |
| TLC, L | 6.10 (1.68) |
| TLC, % predicted | 104.7 (15.8) |
| RV, L | 1.89 (0.88) |
| RV, % predicted | 99.1 (32.9) |
| RV/TLC, % | 29.42 (8.37) |
| Dlco, % predicted | 89.51 (20.10) |
| History of prior lung disease, No. (%) | |
| Asthma | 12 (17.9) |
| COPD | 1 (1.5) |
| No prior lung disease | 54 (80.6) |
| History of smoking, No. (%) | 21 (31.3) |
ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; CLL = chronic lymphocytic leukemia; CML = chronic myelogenous leukemia; Dlco = diffusing capacity for carbon monoxide; HL = Hodgkin’s lymphoma; MDS = myelodysplastic syndrome; NHL = non-Hodgkin’s lymphoma; RV = residual volume; TLC = total lung capacity.
a
Hematopoietic cell transplantation comorbidity index score (HCT-CI) was calculated as described by Sorror.17